Truist raised the firm’s price target on Medtronic (MDT) to $93 from $89 and keeps a Hold rating on the shares after its Q3 earnings beat.

In an “urgent medical device correction,” the company urges clinicians to remind patients to monitor their glucose levels during takeoffs and landings.

Medtronic's stock has been static, not delivering any gains for investors. Click here to find out why MDT stock is a Buy.

Medtronic posted a strong profit for Q3 of fiscal year 2025, though shares were down as its cardiac ablation product success ...

Third-quarter results for Medtronic (NYSE:MDT) included a timeline for a planned label expansion for its automated insulin ...

Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025.

Medtronic (NYSE:MDT) issued an urgent field safety notice in Europe related to multiple versions of its MiniMed insulin pump ...

Medtronic has recalled systems for draining fluid from the brain because of the risk of cracks and leaks, the Food and Drug Administration said Monday. The agency published the Class I notice about ...

Altitude changes during commercial flights may affect the blood glucose levels of people with type 1 diabetes who are treated with insulin pump therapy, according to new research to be presented ...

Shares of Medtronic (NYSE: MDT) are off to a fantastic start ... And in the highly competitive diabetes care segment, the new MiniMed 780G insulin pump system employs AI algorithms to predict and ...